Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies.

TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as ...

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it broadens its pipeline.

BMO Capital Markets agreed to pay more than $40 million to settle U.S. Securities and Exchange Commission charges it failed ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant ...

Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

The ASX slumped further on Monday, with the S&P/ASX 200 index down 1.23% following strong US jobs data, dashing hopes of an ...

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...